HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc07-1794v1 31/2/316    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lavery, L. A. Articles by Lavery, D. C. Search for Related Content PubMed PubMed Citation Articles by Lavery, L. A. Articles by Lavery, D. C. Social Bookmarking                What's this?

Does Anodyne Light Therapy Improve Peripheral Neuropathy in Diabetes?

A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy

From the Department of Surgery, Texas A&M University Health and Science Center College of Medicine, Scott and White Hospital, Temple, Texas

Address correspondence and reprint requests to Lawrence A. Lavery, 703 Highland Spring Ln., Georgetown, TX 78633. E-mail: lklavery{at}yahoo.com

OBJECTIVE—The purpose of this study was to determine the efficacy of anodyne monochromatic infrared photo energy (MIRE) in-home treatments over a 90-day period to improve peripheral sensation and self-reported quality of life in individuals with diabetes.

RESEARCH DESIGN AND METHODS—This was a double-blind, randomized, sham-controlled clinical trail. We randomly assigned 69 individuals with diabetes and a vibration perception threshold (VPT) between 20 and 45 V to two treatment groups: active or sham treatment. Sixty patients (120 limbs) completed the study. Anodyne units were used at home every day for 40 min for 90 days. We evaluated nerve conduction velocities, VPT, Semmes-Weinstein monofilaments (SWM) (4-, 10-, 26-, and 60-g monofilaments), the Michigan Neuropathy Screening Instrument (MNSI), a 10-cm visual analog pain scale, and a neuropathy-specific quality of life instrument. We used a nested repeated-measures multiple ANOVA design. Two sites (great toe and fifth metatarsal) were tested on both the left and right feet of each patient, so two feet were nested within each patient and two sites were nested within each foot. To analyze the ordinal SWM scores, we used a nonparametric factorial analysis for longitudinal data.

RESULTS—There were no significant differences in measures for quality of life, MNSI, VPT, SWM, or nerve conduction velocities in active or sham treatment groups (P > 0.05).

CONCLUSIONS—Anodyne MIRE therapy was no more effective than sham therapy in the treatment of sensory neuropathy in individuals with diabetes.

Abbreviations: MIRE, monochromatic infrared energy • MNSI, Michigan Neuropathy Screening Instrument • NeuroQoL, neuropathy-specific quality of life instrument • RCT, randomized clinical trial • SWM, Semmes-Weinstein monofilament • VPT, vibration perception threshold

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				"Anodyne Therapy" for Diabetic Neuropathy -- No Benefit Journal Watch (General), March 6, 2008; 2008(306): 2 - 2. [Full Text]